Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
1,861
archived clinical trials in
Bladder Cancer

Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery
Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients With Advanced or Unresectable Urothelial Carcinoma of the Bladder
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Cancer Center P2C
563
mi
from 43215
Rochester, MN
Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery
Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients With Advanced or Unresectable Urothelial Carcinoma of the Bladder
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Cancer Center P2C
563
mi
from 43215
Rochester, MN
Click here to add this to my saved trials
Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery
Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients With Advanced or Unresectable Urothelial Carcinoma of the Bladder
Status: Enrolling
Updated:  12/31/1969
Roswell Park Cancer Institute
295
mi
from 43215
Buffalo, NY
Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery
Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients With Advanced or Unresectable Urothelial Carcinoma of the Bladder
Status: Enrolling
Updated: 12/31/1969
Roswell Park Cancer Institute
295
mi
from 43215
Buffalo, NY
Click here to add this to my saved trials
Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery
Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients With Advanced or Unresectable Urothelial Carcinoma of the Bladder
Status: Enrolling
Updated:  12/31/1969
Case Western Reserve Univ
129
mi
from 43215
Cleveland, OH
Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery
Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients With Advanced or Unresectable Urothelial Carcinoma of the Bladder
Status: Enrolling
Updated: 12/31/1969
Case Western Reserve Univ
129
mi
from 43215
Cleveland, OH
Click here to add this to my saved trials
Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery
Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients With Advanced or Unresectable Urothelial Carcinoma of the Bladder
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic Foundation
138
mi
from 43215
Cleveland, OH
Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery
Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients With Advanced or Unresectable Urothelial Carcinoma of the Bladder
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic Foundation
138
mi
from 43215
Cleveland, OH
Click here to add this to my saved trials
Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery
Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients With Advanced or Unresectable Urothelial Carcinoma of the Bladder
Status: Enrolling
Updated:  12/31/1969
Ohio State University Comprehensive Cancer Center
2
mi
from 43215
Columbus, OH
Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery
Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients With Advanced or Unresectable Urothelial Carcinoma of the Bladder
Status: Enrolling
Updated: 12/31/1969
Ohio State University Comprehensive Cancer Center
2
mi
from 43215
Columbus, OH
Click here to add this to my saved trials
Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery
Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients With Advanced or Unresectable Urothelial Carcinoma of the Bladder
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh Cancer Institute (UPCI)
166
mi
from 43215
Pittsburgh, PA
Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery
Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients With Advanced or Unresectable Urothelial Carcinoma of the Bladder
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh Cancer Institute (UPCI)
166
mi
from 43215
Pittsburgh, PA
Click here to add this to my saved trials
Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery
Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients With Advanced or Unresectable Urothelial Carcinoma of the Bladder
Status: Enrolling
Updated:  12/31/1969
University of Texas M D Anderson Cancer Center P2C
991
mi
from 43215
Houston, TX
Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery
Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients With Advanced or Unresectable Urothelial Carcinoma of the Bladder
Status: Enrolling
Updated: 12/31/1969
University of Texas M D Anderson Cancer Center P2C
991
mi
from 43215
Houston, TX
Click here to add this to my saved trials
Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery
Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients With Advanced or Unresectable Urothelial Carcinoma of the Bladder
Status: Enrolling
Updated:  12/31/1969
University Health Network Princess Margaret Cancer Center P2C
316
mi
from 43215
Toronto,
Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery
Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients With Advanced or Unresectable Urothelial Carcinoma of the Bladder
Status: Enrolling
Updated: 12/31/1969
University Health Network Princess Margaret Cancer Center P2C
316
mi
from 43215
Toronto,
Click here to add this to my saved trials
Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery
Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients With Advanced or Unresectable Urothelial Carcinoma of the Bladder
Status: Enrolling
Updated:  12/31/1969
University of Colorado Hospital
1153
mi
from 43215
Aurora, CO
Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery
Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients With Advanced or Unresectable Urothelial Carcinoma of the Bladder
Status: Enrolling
Updated: 12/31/1969
University of Colorado Hospital
1153
mi
from 43215
Aurora, CO
Click here to add this to my saved trials
Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery
Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients With Advanced or Unresectable Urothelial Carcinoma of the Bladder
Status: Enrolling
Updated:  12/31/1969
MedStar Georgetown University Hospital
328
mi
from 43215
Washington,
Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery
Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients With Advanced or Unresectable Urothelial Carcinoma of the Bladder
Status: Enrolling
Updated: 12/31/1969
MedStar Georgetown University Hospital
328
mi
from 43215
Washington,
Click here to add this to my saved trials
Improving Clinical Staging for Muscle Invasive Bladder Cancer Through Molecular Profiling and Improved Imaging
Improving Clinical Staging for Muscle Invasive Bladder Cancer Through Molecular Profiling and Improved Imaging
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
995
mi
from 43215
Houston, TX
Improving Clinical Staging for Muscle Invasive Bladder Cancer Through Molecular Profiling and Improved Imaging
Improving Clinical Staging for Muscle Invasive Bladder Cancer Through Molecular Profiling and Improved Imaging
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
995
mi
from 43215
Houston, TX
Click here to add this to my saved trials
TAA-Specific CTLS for Solid Tumors (TACTASOM)
Tumor Associated Antigen (TAA)-Specific Cytotoxic T-Lymphocytes Administered to Patients With Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Houston Methodist Hospital
995
mi
from 43215
Houston, TX
TAA-Specific CTLS for Solid Tumors (TACTASOM)
Tumor Associated Antigen (TAA)-Specific Cytotoxic T-Lymphocytes Administered to Patients With Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Houston Methodist Hospital
995
mi
from 43215
Houston, TX
Click here to add this to my saved trials
TAA-Specific CTLS for Solid Tumors (TACTASOM)
Tumor Associated Antigen (TAA)-Specific Cytotoxic T-Lymphocytes Administered to Patients With Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Texas Children's Hospital
995
mi
from 43215
Houston, TX
TAA-Specific CTLS for Solid Tumors (TACTASOM)
Tumor Associated Antigen (TAA)-Specific Cytotoxic T-Lymphocytes Administered to Patients With Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Texas Children's Hospital
995
mi
from 43215
Houston, TX
Click here to add this to my saved trials
Evaluate the Response to 2 Induction Courses (12 Intravesical Instillations) of Bacillus Calmette-Guérin (BCG) for High Risk Superficial Bladder Cancer
Phase II Study to Evaluate the Response to 2 Induction Courses (12 Intravesical Instillations) of Bacillus Calmette-Guérin (BCG) for High Risk Superficial Bladder Cancer
Status: Enrolling
Updated:  12/31/1969
Memoral Sloan Kettering Cancer Center
449
mi
from 43215
Basking Ridge, NJ
Evaluate the Response to 2 Induction Courses (12 Intravesical Instillations) of Bacillus Calmette-Guérin (BCG) for High Risk Superficial Bladder Cancer
Phase II Study to Evaluate the Response to 2 Induction Courses (12 Intravesical Instillations) of Bacillus Calmette-Guérin (BCG) for High Risk Superficial Bladder Cancer
Status: Enrolling
Updated: 12/31/1969
Memoral Sloan Kettering Cancer Center
449
mi
from 43215
Basking Ridge, NJ
Click here to add this to my saved trials
Evaluate the Response to 2 Induction Courses (12 Intravesical Instillations) of Bacillus Calmette-Guérin (BCG) for High Risk Superficial Bladder Cancer
Phase II Study to Evaluate the Response to 2 Induction Courses (12 Intravesical Instillations) of Bacillus Calmette-Guérin (BCG) for High Risk Superficial Bladder Cancer
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
480
mi
from 43215
New York, NY
Evaluate the Response to 2 Induction Courses (12 Intravesical Instillations) of Bacillus Calmette-Guérin (BCG) for High Risk Superficial Bladder Cancer
Phase II Study to Evaluate the Response to 2 Induction Courses (12 Intravesical Instillations) of Bacillus Calmette-Guérin (BCG) for High Risk Superficial Bladder Cancer
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
480
mi
from 43215
New York, NY
Click here to add this to my saved trials
Evaluate the Response to 2 Induction Courses (12 Intravesical Instillations) of Bacillus Calmette-Guérin (BCG) for High Risk Superficial Bladder Cancer
Phase II Study to Evaluate the Response to 2 Induction Courses (12 Intravesical Instillations) of Bacillus Calmette-Guérin (BCG) for High Risk Superficial Bladder Cancer
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Monmouth
470
mi
from 43215
Middletown, NJ
Evaluate the Response to 2 Induction Courses (12 Intravesical Instillations) of Bacillus Calmette-Guérin (BCG) for High Risk Superficial Bladder Cancer
Phase II Study to Evaluate the Response to 2 Induction Courses (12 Intravesical Instillations) of Bacillus Calmette-Guérin (BCG) for High Risk Superficial Bladder Cancer
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Monmouth
470
mi
from 43215
Middletown, NJ
Click here to add this to my saved trials
Evaluate the Response to 2 Induction Courses (12 Intravesical Instillations) of Bacillus Calmette-Guérin (BCG) for High Risk Superficial Bladder Cancer
Phase II Study to Evaluate the Response to 2 Induction Courses (12 Intravesical Instillations) of Bacillus Calmette-Guérin (BCG) for High Risk Superficial Bladder Cancer
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Commack
515
mi
from 43215
Commack, NY
Evaluate the Response to 2 Induction Courses (12 Intravesical Instillations) of Bacillus Calmette-Guérin (BCG) for High Risk Superficial Bladder Cancer
Phase II Study to Evaluate the Response to 2 Induction Courses (12 Intravesical Instillations) of Bacillus Calmette-Guérin (BCG) for High Risk Superficial Bladder Cancer
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Commack
515
mi
from 43215
Commack, NY
Click here to add this to my saved trials
Evaluate the Response to 2 Induction Courses (12 Intravesical Instillations) of Bacillus Calmette-Guérin (BCG) for High Risk Superficial Bladder Cancer
Phase II Study to Evaluate the Response to 2 Induction Courses (12 Intravesical Instillations) of Bacillus Calmette-Guérin (BCG) for High Risk Superficial Bladder Cancer
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Westchester
493
mi
from 43215
Harrison, NY
Evaluate the Response to 2 Induction Courses (12 Intravesical Instillations) of Bacillus Calmette-Guérin (BCG) for High Risk Superficial Bladder Cancer
Phase II Study to Evaluate the Response to 2 Induction Courses (12 Intravesical Instillations) of Bacillus Calmette-Guérin (BCG) for High Risk Superficial Bladder Cancer
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Westchester
493
mi
from 43215
Harrison, NY
Click here to add this to my saved trials
A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]
A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer After Failure With Platinum-Containing Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Emory University/Winship Cancer Institute
432
mi
from 43215
Atlanta, GA
A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]
A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer After Failure With Platinum-Containing Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Emory University/Winship Cancer Institute
432
mi
from 43215
Atlanta, GA
Click here to add this to my saved trials
A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]
A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer After Failure With Platinum-Containing Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Comprehensive Cancer Centers of Nevada
1767
mi
from 43215
Las Vegas, NV
A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]
A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer After Failure With Platinum-Containing Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Comprehensive Cancer Centers of Nevada
1767
mi
from 43215
Las Vegas, NV
Click here to add this to my saved trials
A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]
A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer After Failure With Platinum-Containing Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Duke Cancer Center
354
mi
from 43215
Durham, NC
A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]
A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer After Failure With Platinum-Containing Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Duke Cancer Center
354
mi
from 43215
Durham, NC
Click here to add this to my saved trials
A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]
A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer After Failure With Platinum-Containing Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Bon Secours St. Francis Hospital
355
mi
from 43215
Greenville, SC
A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]
A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer After Failure With Platinum-Containing Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Bon Secours St. Francis Hospital
355
mi
from 43215
Greenville, SC
Click here to add this to my saved trials
A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]
A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer After Failure With Platinum-Containing Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Vanderbilt-Ingram Cancer Center
334
mi
from 43215
Nashville, TN
A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]
A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer After Failure With Platinum-Containing Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Vanderbilt-Ingram Cancer Center
334
mi
from 43215
Nashville, TN
Click here to add this to my saved trials
A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]
A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer After Failure With Platinum-Containing Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Royal Brisbane and Women's Hospital; Medical Oncology
9156
mi
from 43215
Herston,
A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]
A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer After Failure With Platinum-Containing Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Royal Brisbane and Women's Hospital; Medical Oncology
9156
mi
from 43215
Herston,
Click here to add this to my saved trials
A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]
A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer After Failure With Platinum-Containing Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Georgetown University Medical Center Lombardi Cancer Center
328
mi
from 43215
Washington,
A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]
A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer After Failure With Platinum-Containing Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Georgetown University Medical Center Lombardi Cancer Center
328
mi
from 43215
Washington,
Click here to add this to my saved trials
Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer
Status: Enrolling
Updated:  12/31/1969
Emory University Hospital Midtown
434
mi
from 43215
Atlanta, GA
Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer
Status: Enrolling
Updated: 12/31/1969
Emory University Hospital Midtown
434
mi
from 43215
Atlanta, GA
Click here to add this to my saved trials
Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer
Status: Enrolling
Updated:  12/31/1969
Decatur Memorial Hospital
314
mi
from 43215
Decatur, IL
Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer
Status: Enrolling
Updated: 12/31/1969
Decatur Memorial Hospital
314
mi
from 43215
Decatur, IL
Click here to add this to my saved trials
Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer
Status: Enrolling
Updated:  12/31/1969
OSF Saint Francis Medical Center
349
mi
from 43215
Peoria, IL
Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer
Status: Enrolling
Updated: 12/31/1969
OSF Saint Francis Medical Center
349
mi
from 43215
Peoria, IL
Click here to add this to my saved trials
Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer
Status: Enrolling
Updated:  12/31/1969
McFarland Clinic PC-William R Bliss Cancer Center
570
mi
from 43215
Ames, IA
Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer
Status: Enrolling
Updated: 12/31/1969
McFarland Clinic PC-William R Bliss Cancer Center
570
mi
from 43215
Ames, IA
Click here to add this to my saved trials
Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer
Status: Enrolling
Updated:  12/31/1969
University of Oklahoma Health Sciences Center
841
mi
from 43215
Oklahoma City, OK
Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer
Status: Enrolling
Updated: 12/31/1969
University of Oklahoma Health Sciences Center
841
mi
from 43215
Oklahoma City, OK
Click here to add this to my saved trials
Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer
Status: Enrolling
Updated:  12/31/1969
NRG Oncology
415
mi
from 43215
Philadelphia, PA
Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer
Status: Enrolling
Updated: 12/31/1969
NRG Oncology
415
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer
Status: Enrolling
Updated:  12/31/1969
AIS Cancer Center at San Joaquin Community Hospital
1979
mi
from 43215
Bakersfield, CA
Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer
Status: Enrolling
Updated: 12/31/1969
AIS Cancer Center at San Joaquin Community Hospital
1979
mi
from 43215
Bakersfield, CA
Click here to add this to my saved trials
Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer
Status: Enrolling
Updated:  12/31/1969
Marin General Hospital
2109
mi
from 43215
Greenbrae, CA
Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer
Status: Enrolling
Updated: 12/31/1969
Marin General Hospital
2109
mi
from 43215
Greenbrae, CA
Click here to add this to my saved trials
Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer
Status: Enrolling
Updated:  12/31/1969
Los Angeles County-USC Medical Center
1970
mi
from 43215
Los Angeles, CA
Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer
Status: Enrolling
Updated: 12/31/1969
Los Angeles County-USC Medical Center
1970
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer
Status: Enrolling
Updated:  12/31/1969
U.S.C./Norris Comprehensive Cancer Center
1970
mi
from 43215
Los Angeles, CA
Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer
Status: Enrolling
Updated: 12/31/1969
U.S.C./Norris Comprehensive Cancer Center
1970
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer
Status: Enrolling
Updated:  12/31/1969
Stanford Cancer Institute Palo Alto
2101
mi
from 43215
Palo Alto, CA
Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer
Status: Enrolling
Updated: 12/31/1969
Stanford Cancer Institute Palo Alto
2101
mi
from 43215
Palo Alto, CA
Click here to add this to my saved trials
Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer
Status: Enrolling
Updated:  12/31/1969
University of California-Davis Comprehensive Cancer Ctr
2042
mi
from 43215
Sacramento, CA
Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer
Status: Enrolling
Updated: 12/31/1969
University of California-Davis Comprehensive Cancer Ctr
2042
mi
from 43215
Sacramento, CA
Click here to add this to my saved trials
Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer
Status: Enrolling
Updated:  12/31/1969
University of Colorado Hospital
1153
mi
from 43215
Aurora, CO
Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer
Status: Enrolling
Updated: 12/31/1969
University of Colorado Hospital
1153
mi
from 43215
Aurora, CO
Click here to add this to my saved trials
Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer
Status: Enrolling
Updated:  12/31/1969
Penrose-Saint Francis Healthcare
1163
mi
from 43215
Colorado Springs, CO
Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer
Status: Enrolling
Updated: 12/31/1969
Penrose-Saint Francis Healthcare
1163
mi
from 43215
Colorado Springs, CO
Click here to add this to my saved trials
Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer
Status: Enrolling
Updated:  12/31/1969
Memorial Hospital Central
1162
mi
from 43215
Colorado Springs, CO
Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer
Status: Enrolling
Updated: 12/31/1969
Memorial Hospital Central
1162
mi
from 43215
Colorado Springs, CO
Click here to add this to my saved trials
Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer
Status: Enrolling
Updated:  12/31/1969
Poudre Valley Hospital
1158
mi
from 43215
Fort Collins, CO
Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer
Status: Enrolling
Updated: 12/31/1969
Poudre Valley Hospital
1158
mi
from 43215
Fort Collins, CO
Click here to add this to my saved trials
Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer
Status: Enrolling
Updated:  12/31/1969
Christiana Care Health System - Christiana Hospital
385
mi
from 43215
Newark, DE
Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer
Status: Enrolling
Updated: 12/31/1969
Christiana Care Health System - Christiana Hospital
385
mi
from 43215
Newark, DE
Click here to add this to my saved trials
Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer
Status: Enrolling
Updated:  12/31/1969
Beebe Health Campus
433
mi
from 43215
Rehoboth Beach, DE
Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer
Status: Enrolling
Updated: 12/31/1969
Beebe Health Campus
433
mi
from 43215
Rehoboth Beach, DE
Click here to add this to my saved trials
Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer
Status: Enrolling
Updated:  12/31/1969
Moffitt Cancer Center
823
mi
from 43215
Tampa, FL
Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer
Status: Enrolling
Updated: 12/31/1969
Moffitt Cancer Center
823
mi
from 43215
Tampa, FL
Click here to add this to my saved trials
Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer
Status: Enrolling
Updated:  12/31/1969
Emory University Hospital-Winship Cancer Institute
436
mi
from 43215
Atlanta, GA
Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer
Status: Enrolling
Updated: 12/31/1969
Emory University Hospital-Winship Cancer Institute
436
mi
from 43215
Atlanta, GA
Click here to add this to my saved trials
Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer
Status: Enrolling
Updated:  12/31/1969
Emory Saint Joseph's Hospital
426
mi
from 43215
Atlanta, GA
Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer
Status: Enrolling
Updated: 12/31/1969
Emory Saint Joseph's Hospital
426
mi
from 43215
Atlanta, GA
Click here to add this to my saved trials
Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer
Status: Enrolling
Updated:  12/31/1969
Northeast Georgia Medical Center-Gainesville
393
mi
from 43215
Gainesville, GA
Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer
Status: Enrolling
Updated: 12/31/1969
Northeast Georgia Medical Center-Gainesville
393
mi
from 43215
Gainesville, GA
Click here to add this to my saved trials
Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer
Status: Enrolling
Updated:  12/31/1969
Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
626
mi
from 43215
Savannah, GA
Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer
Status: Enrolling
Updated: 12/31/1969
Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
626
mi
from 43215
Savannah, GA
Click here to add this to my saved trials
Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer
Status: Enrolling
Updated:  12/31/1969
Saint Luke's Mountain States Tumor Institute
1714
mi
from 43215
Boise, ID
Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer
Status: Enrolling
Updated: 12/31/1969
Saint Luke's Mountain States Tumor Institute
1714
mi
from 43215
Boise, ID
Click here to add this to my saved trials
Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer
Status: Enrolling
Updated:  12/31/1969
Saint Luke's Mountain States Tumor Institute - Fruitland
1750
mi
from 43215
Fruitland, ID
Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer
Status: Enrolling
Updated: 12/31/1969
Saint Luke's Mountain States Tumor Institute - Fruitland
1750
mi
from 43215
Fruitland, ID
Click here to add this to my saved trials